- Home
- LXRX vs GOSS Comparison
LXRX vs GOSS Comparison
Compare LXRX & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXRX
- GOSS
- Stock Information
- Founded
- LXRX 1995
- GOSS 2015
- Country
- LXRX United States
- GOSS United States
- Employees
- LXRX 103
- GOSS N/A
- Industry
- LXRX Biotechnology: Pharmaceutical Preparations
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- LXRX Health Care
- GOSS Health Care
- Exchange
- LXRX Nasdaq
- GOSS Nasdaq
- Market Cap
- LXRX 388.6M
- GOSS 347.8M
- IPO Year
- LXRX 2000
- GOSS 2019
- Fundamental
- Price
- LXRX $1.07
- GOSS $2.00
- Analyst Decision
- LXRX Buy
- GOSS Strong Buy
- Analyst Count
- LXRX 4
- GOSS 4
- Target Price
- LXRX $3.67
- GOSS $8.25
- AVG Volume (30 Days)
- LXRX 3.5M
- GOSS 2.9M
- Earning Date
- LXRX 08-06-2025
- GOSS 08-11-2025
- Dividend Yield
- LXRX N/A
- GOSS N/A
- EPS Growth
- LXRX N/A
- GOSS N/A
- EPS
- LXRX N/A
- GOSS N/A
- Revenue
- LXRX $31,213,000.00
- GOSS $124,590,000.00
- Revenue This Year
- LXRX N/A
- GOSS N/A
- Revenue Next Year
- LXRX N/A
- GOSS $65.50
- P/E Ratio
- LXRX N/A
- GOSS N/A
- Revenue Growth
- LXRX 1251.21
- GOSS N/A
- 52 Week Low
- LXRX $0.28
- GOSS $0.66
- 52 Week High
- LXRX $2.25
- GOSS $2.18
- Technical
- Relative Strength Index (RSI)
- LXRX 52.30
- GOSS 70.04
- Support Level
- LXRX $1.00
- GOSS $1.72
- Resistance Level
- LXRX $1.11
- GOSS $2.18
- Average True Range (ATR)
- LXRX 0.10
- GOSS 0.17
- MACD
- LXRX -0.03
- GOSS 0.03
- Stochastic Oscillator
- LXRX 16.28
- GOSS 76.32
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.